Circulating leptin levels are associated with adiposity in survivors of childhood brain tumors

E. Danielle Sims1,2, William J. Jennings1,2, Brianna Empringham1,2, Adam Fleming1,2, Carol Portwine1,3, Donna L. Johnston4, Shayna M. Zelcer5, Shahrad Rod Rassekh6, Sarah Burrow7, Lehana Thabane8,9,10,11 & M. Constantine Samaan1,2,8*

Survivors of Childhood Brain Tumors (SCBT) are at a higher risk of developing cardiovascular disease and type 2 diabetes compared to the general population. Adiposity is an important risk factor for the development of these outcomes, and identifying biomarkers of adiposity may help the stratification of survivors based on their cardiovascular risk or allow for early screening and interventions to improve cardiometabolic outcomes. Leptin is an adipokine that positively correlates with the adipose mass in the general population and is a predictor of adverse cardiometabolic outcomes, yet its association with adiposity in SCBT has not been studied. The aim of this study was to determine if leptin levels are associated with the adipose mass in SCBT, and to define its predictors. This cross-sectional study included 74 SCBT (n = 32 females) with 126 non-cancer controls (n = 59 females). Total adiposity was measured using Bioelectrical Impedance Analysis (BIA) and central adiposity was measured using waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR). We used multivariable linear regression analysis to determine if leptin predicts adiposity in SCBT and adjusted for age, sex, puberty, and cancer status. Leptin correlated strongly with total (p < 0.001) and central (WHR p = 0.001; WHtR p < 0.001) adiposity in SCBT and non-cancer controls. In conclusion, leptin is a potential biomarker for adiposity in SCBT, and further investigation is needed to clarify if leptin is a predictor of future cardiometabolic risk in SCBT.

Cardiovascular disease is a leading cause of morbidity and mortality, accounting for approximately 17.6 million deaths per annum globally1,2. While cardiovascular diseases are a significant burden on healthcare systems in the general population1–4, specific populations seem to have a higher propensity for these diseases than others, and one such cohort includes the survivors of childhood cancer. Cardiovascular diseases are one of the leading causes of non-cancer related mortality in this population, and accounts for 20% of mortality rates within 15 years of cancer therapy5–8.

Within the cancer survivorship subgroups, the Survivors of Childhood Brain Tumors (SCBT) have a significant risk of premature cardiovascular diseases and one of their major risk factors, type 2 diabetes mellitus9,10. SCBT have a 29-fold higher risk for stroke and a two-fold higher risk of type 2 diabetes compared to non-cancer controls9,11. Cardiometabolic disorders are emerging as an important determinant of longevity and quality of life in SCBT4, and there is a critical necessity to identify the risk factors and biomarkers of cardiometabolic risk to personalize preventative and therapeutic strategies to improve outcomes in this population.

1Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 2Division of Pediatric Endocrinology, McMaster Children’s Hospital, Hamilton, Ontario, Canada. 3Division of Pediatric Hematology/Oncology, McMaster Children’s Hospital, Hamilton, Ontario, Canada. 4Division of Pediatric Hematology/Oncology, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada. 5Pediatric Hematology Oncology, Children’s Hospital, London Health Sciences Center, London, Ontario, Canada. 6Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, British Columbia Children’s Hospital, Vancouver, BC, Canada. 7Division of Orthopedic Surgery, Department of Surgery, McMaster University Medical Centre, Hamilton, Ontario, Canada. 8Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. 9Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada. 10Centre for Evaluation of Medicines, St. Joseph’s Health Care, Hamilton, Ontario, Canada. 11Biostatistics Unit, St Joseph’s Healthcare-Hamilton, Hamilton, Ontario, Canada. *email: samaanc@mcmaster.ca
Table 1. Study Population Characteristics. Abbreviations: SCBT, survivors of childhood brain tumors; SD, standard deviation; BMI, Body Mass Index. The data for height and weight z-scores are reported as a mean with range.

| Variables                   | SCBT (n = 74) | Controls (n = 126) | P-value |
|-----------------------------|--------------|--------------------|---------|
| Age at enrollment (years)   | 15.08 ± 7.27 | 14.04 ± 2.72       | 0.633   |
| Sex, No. (%)                |              |                    |         |
| Male                        | 42 (56.80)   | 67 (53.20)         | —       |
| Female                      | 32 (43.20)   | 59 (46.80)         | —       |
| Height (cm)                 | 151.13 ± 25.22 | 162.19 ± 15.13   | <0.001  |
| Height z-score              | −0.24 (−2.6−1.56) | 0.28 (−2.01−1.99) | <0.001  |
| Weight (kg)                 | 53.32 ± 24.58 | 60.09 ± 21.97     | 0.003   |
| Weight z-score              | −0.10 (−1.69−2.23) | 0.20 (−1.45−4.42) | 0.001   |
| BMI percentile (%)          | 63.54 ± 30.83 | 63.46 ± 30.37     | 0.981   |
| Fat mass percentage (%FM)   | 24.99 ± 9.99  | 22.68 ± 9.79       | 0.105   |
| Waist-to-hip ratio (n = 198) | 0.87 ± 0.07  | 0.83 ± 0.10        | 0.001   |
| Waist-to-height ratio (n = 198) | 0.48 ± 0.07 | 0.45 ± 0.08        | 0.014   |
| Leptin (ng/ml; n = 47 SCBT, n = 97 controls) | 14.74 ± 21.76 | 10.62 ± 12.11 | 0.770   |

The presence of excess adiposity is a major risk factor for cardiovascular diseases and type 2 diabetes mellitus in the general population\(^{12,13}\). Importantly, SCBT have an important phenotypic difference when compared to non-cancer controls with excess total and central adiposity in the presence of similar Body Mass Index (BMI)\(^{14−18}\). This is critically important, as higher adiposity during childhood carries over to adulthood and is associated with adverse cardiometabolic outcomes in the general population\(^{12,13}\), but the path to excess adiposity is unknown in SCBT\(^{19−22}\).

Leptin is an adipokine that serves as a biomarker of the fat mass in the general population\(^{23−26}\), and hyperleptinemia is a predictor of several cardiometabolic outcomes\(^{27−31}\) including diabetes\(^{27,28}\), glucose intolerance\(^{29}\), insulin resistance\(^{30}\), coronary events\(^{30}\), hypertension\(^{31}\), and features of the metabolic syndrome\(^{32}\). However, the relationship between leptin levels, adiposity, and cardiometabolic outcomes in SCBT is not known. In this paper, we tested the hypothesis that leptin is associated with adiposity in SCBT in a similar way to this association in non-cancer controls. We also set out to define the potential predictors of leptin levels in SCBT.

Results

Demographics. The population characteristics are reported in Table 1. The SCBT group was recruited at 6 ± 4.2 years post completion of cancer therapy, and included 74 SCBT (n = 32 female, 43.20%) and 126 non-cancer controls (n = 59 female, 46.80%). The groups had similar age distribution (SCBT: 15.08 ± 7.27 years; controls: 14.04 ± 2.72 years). SCBT were shorter (SCBT: 151.13 ± 25.22 cm; controls: 162.19 ± 15.13 cm) and had lower weight (SCBT: 53.32 ± 24.58 kg; controls: 60.09 ± 21.97 kg) compared to non-cancer controls.

There were no differences in BMI percentiles in the two groups (SCBT: 63.54 ± 30.83; controls: 63.46 ± 30.37). On assessment of adiposity phenotype in participants, total adiposity trended higher in survivors compared to non-cancer controls measured via fat mass percentage yet this was not statistically significant (%FM; SCBT: 24.99 ± 9.99%; controls: 22.68 ± 9.79%, p-value 0.105). In addition, SCBT had higher central adiposity compared to non-cancer controls including waist-to-hip ratio (WHR; SCBT: 0.87 ± 0.07, controls: 0.83 ± 0.10, p-value 0.001) and waist-to-height ratio (WHtR; SCBT: 0.48 ± 0.07, controls: 0.45 ± 0.08, p-value 0.014). The majority of both groups have either completed or were undergoing pubertal development (SCBT n = 51, 68.9%, controls n = 109, 86.5%, p-value 0.005).

Brain tumor characteristics. The characteristics of the tumors in SCBT group are presented in Table 2. The most common tumor type was low grade glioma (n = 42, 36.80%). Tumors were distributed equally between the supratentorial (n = 35, 47.30%) and infratentorial (n = 39, 52.70%) regions. The majority of survivors were surgically treated (n = 57, 77.00%), and some had radiotherapy (n = 30, 40.50%) and chemotherapy (n = 36, 48.60%) as per standard protocols\(^{10−23}\). Leptin levels correlated with surgery (r = 0.35, p-value 0.015) and radiotherapy (r = 0.43, p-value 0.002) but not chemotherapy (r = 0.18, p-value 0.230).

Leptin and adiposity measures in SCBT. To determine if leptin levels were different between SCBT and non-cancer controls, we measured plasma leptin levels using Enzyme Linked Immunosorbent Assay (ELISA) technique. The average leptin levels were similar between the two groups (SCBT: 14.74 ± 21.76 ng/ml vs controls: 10.62 ± 12.11 ng/ml, p = 0.770).

To determine if leptin was associated with the fat mass, we performed an unadjusted Pearson zero-order correlation analysis and an age, sex, and puberty-adjusted partial correlation analysis (Table 3). Leptin correlated with total adiposity (Unadjusted r = 0.68; Adjusted r = 0.67; p < 0.001). Leptin also correlated with central adiposity measures including a weak positive correlation with WHR (Unadjusted r = 0.19; Adjusted r = 0.29; p < 0.001) and a strongly positive correlation with WHtR (Unadjusted r = 0.58; Adjusted r = 0.63; p < 0.001).
To assess if leptin was associated with the fat mass in SCBT, we conducted multivariable linear regression analyses (Table 3). Leptin was associated with total adiposity (%FM $\beta = 0.67$, $p < 0.001$) and central adiposity (WHR $\beta = 0.30$, $p < 0.001$; WHtR $\beta = 0.67$, $p < 0.001$). Furthermore, having a brain tumor was associated with having a higher %FM ($\beta = 0.18$, $p < 0.001$) as well as central adiposity (WHR $\beta = 0.24$, $p < 0.001$; WHtR $\beta = 0.17$, $p < 0.001$). Treatments including surgery, radiotherapy, or chemotherapy had no effect on the association between adiposity and leptin levels (data not shown).

Taken together, these data demonstrated that leptin was a biomarker of total and central adiposity in SCBT and in non-cancer controls.

### Discussion

Up to 80% of children diagnosed with certain subtypes of brain tumors today are likely to survive their diagnosis $^{34}$, yet the emergence of cardiometabolic disorders in survivors may undermine these survival rates and contribute to premature mortality $^{35–40}$. Identifying biomarkers of the fat mass in SCBT may help predict who is at risk of excess adiposity, a known risk factor for the development of cardiometabolic disorders. The prediction of adiposity may allow risk stratification and the targeting of those in need of early aggressive interventions to improve survival and quality of life in survivors.

We demonstrate that leptin was a robust biomarker of total and central adiposity in SCBT, and that this trend was similar to the one noted in the non-cancer control group. To our knowledge, this is the first report of leptin assessment in SCBT in comparison to a non-cancer control group across a range of BMIs and adiposity levels.

In one group of brain tumors, Craniopharyngioma, it has been reported that patients develop hypothalamic obesity and hyperleptinemia $^{41,42}$. The latter study by Shaikh et al. included obese participants with additional subtypes of brain tumors beside Craniopharyngioma, as well as a non-brain tumor group e.g. Histiocytosis, Retinoblastoma. In a cross-sectional design, the investigators used DXA scans to compare adiposity in the tumors

| Variables | No. (%) |
|-----------|---------|
| Brain tumor type | |
| Non-NF-1, low grade glioma | 31 (41.90) |
| PNET/Medulloblastoma | 16 (21.60) |
| NF-1, low grade glioma | 11 (14.90) |
| CNS germ cell tumors | 6 (8.10) |
| Subependymal giant cell astrocytoma | 3 (4.10) |
| Ependymoma | 2 (2.70) |
| Meningioma | 1 (1.40) |
| Craniopharyngioma | 2 (2.70) |
| Other | 2 (2.70) |
| Brain tumor location | |
| Supratentorial | 35 (47.30) |
| Infratentorial | 39 (52.70) |
| Brain tumor treatments | |
| Surgery | 57 (77.00) |
| Radiotherapy | 30 (40.50) |
| Chemotherapy | 36 (48.60) |

Table 2. Brain tumor characteristics (n = 74). Abbreviations: CNS, Central Nervous System; PNET, Primitive Neuroectodermal Tumor; NF-1, Neurofibromatosis Type 1.

| Variable | Standardized coefficient $\beta$ | Correlations | p-value |
|----------|---------------------------------|--------------|---------|
| Leptin | 0.67 | 0.68 | 0.67 | <0.001 |
| Cancer vs. Control Group | 0.18 | 0.09 | 0.26 | <0.001 |
| Waist-to-hip ratio | | | |
| Leptin | 0.30 | 0.19 | 0.29 | <0.001 |
| Cancer vs. Control Group | 0.24 | 0.25 | 0.26 | <0.001 |
| Waist-to-height ratio | | | |
| Leptin | 0.67 | 0.58 | 0.63 | <0.001 |
| Cancer vs. Control Group | 0.17 | 0.17 | 0.22 | <0.001 |

Table 3. Regression analyses and correlations of predictors of leptin adjusted for age, sex, puberty, and cancer status. Abbreviations: BMI, Body Mass Index; CI, confidence interval; %FM, fat mass percentage.
group with two other groups—congenital hypopituitarism and simple obesity. The study had a smaller sample size when compared to our study\(^4\). The direct comparisons between our data and this study were limited due to these differences.

Leptin is a 16 kDa peptide hormone secreted mainly by the adipocyte and is encoded by the obese (OB) gene in humans that is located on chromosome 7\(^23,43\). The leptin receptor is preferentially expressed in hypothalamic nuclei including the ventromedial and dorsomedial nuclei, and the arcuate nucleus\(^44,46\), where it plays a critical role in regulating energy homeostasis through its role in satiety regulation and metabolic rate\(^22,47-50\). Excess caloric consumption raises leptin levels which increases energy expenditure while suppressing appetite\(^51,52\).

Leptin levels are also sensitive to changes in adiposity\(^53,54\). Weight loss leads to a reduction in leptin concentrations, likely due to a reduction in adipose tissue production of the adipokine\(^53,54\), and the opposite effect is seen in obesity\(^55\). Accordingly, leptin levels positively correlate with BMI, waist circumference and total adiposity in the general pediatric and adult populations\(^4,24,25,56,57\). Furthermore, females have higher circulating leptin levels compared to males in children and adults\(^18,59\). This makes leptin a potential biomarker of the response to interventions that target adiposity in SCBT.

While genetic leptin deficiency in humans is associated with early onset obesity\(^60,61\), leptin resistance at a hypothalamic level may play an important role in the development of diet-induced obesity\(^22,35\).

Leptin has also served as a biomarker for cardiometabolic outcomes\(^24,25,27-31,56\). Leptin levels positively correlate with fasting insulin concentrations\(^27\), and it is a predictor of glucose intolerance, insulin resistance and the metabolic syndrome independently of baseline obesity in the general population\(^29\). In men, increased leptin levels are a predictor for developing diabetes independently of basal adiposity, insulin resistance, glucose or age\(^7\). Also, elevated levels of leptin have been shown to be a significant predictor of coronary events\(^30\) and hypertension\(^31\).

In children, leptin is also a predictor of BMI, fasting insulin and triglycerides\(^57\).

Further research is required to determine if leptin can similarly be used as a potential biomarker to predict future cardiometabolic outcomes in the SCBT population similarly to the general population.

Leptin is secreted in proportion to the body’s fat mass, and reductions in its levels may induce over-feeding and weight gain\(^66-68\). However, the potential of leptin as a therapeutic weight-loss agent is limited since exogenous leptin delivery is associated with resistance to its effects and induces only mild physiological responses during diet-induced obesity\(^66-68\). In humans, obesity is not linked to leptin deficiency but rather to leptin insensitivity and factors that may improve leptin sensitivity have been studied\(^89\). For example, Amylin is a hormone that is co-secreted from beta cells along with insulin and is a powerful leptin stabilizer\(^90,91\). Additionally, the Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist Exendin-4\(^72\), agonists of the melanocortin 4 receptor (MCR4)\(^73\) and the gut hormones PYY and Cholecystokinin\(^74,75\) have all shown success in eliciting sensitization of central leptin actions. Future pediatric studies should focus on understanding the interactions between leptin and these hormones in an attempt to decipher the mechanisms of leptin action and potential augmentation strategies that may be clinically relevant.

The inclusion of a non-cancer control group in comparison with SCBT, and the similar results noted between groups provides confidence in the results and indicate that leptin is a useful adiposity biomarker in SCBT. The determination that leptin is a predictor of total and central adiposity in SCBT is novel and provides a baseline for future studies of adiposity in this population.

One of the limitations of this study is the lack of long-term follow-up data regarding the association of leptin with long-term cardiometabolic outcomes. Longitudinal follow-up and a sample size that allows for subgroup analyses based on tumor subtype will help predict which groups are at risk of adverse cardiometabolic outcomes to allow early intervention.

In conclusion, this cross-sectional study demonstrated that leptin is a biomarker of total and central adiposity in SCBT. Further investigation into leptin as a potential marker of future cardiovascular disease and type 2 diabetes in SCBT is needed.

It may also help stratify those in need of early interventions to prevent and treat cardiometabolic disorders in this population of cancer survivors.

**Methods**

**Participants.** The complete study methodology has been reported previously\(^76,77\). This is a secondary analysis of cross-sectional data from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE study)\(^8,76,77\). The Hamilton Integrated Research Ethics Board has approved this project. Study procedures were carried out in accordance with the relevant guidelines and legal regulations. Male and female participants, who were 5 years or older, were consecutively recruited from McMaster Children’s Hospital (Hamilton, Ontario, Canada) from November 2012 to December 2016. Participants of all ethnicities with no history of autoimmune diseases or infections or having been treated with immunosuppressive therapy within 15 days of participation were eligible for recruitment into the study.

All participants provided written informed consent. Participants 16 years and older provided their own consent. For participants between 7–15 years of age, assent as well as parental/guardian consent was obtained. Participants under 7 years of age were included in the study with parental consent.

**Anthropometric and clinical measurements.** Data on age, sex, puberty, and ethnicity were collected using standardized questionnaires. To determine the medical history of SCBT, including diagnostic and treatment data, we consulted medical records.

Height was measured to the closest 0.1 cm using a stadiometer and weight to the nearest 0.1 kg with an electronic scale (Seca, USA). Weight and height measurements were used to determine BMI (kg/m\(^2\)). Furthermore, BMI percentile and BMI z-score were classified using the Children’s BMI Tool for Schools\(^86\) and the Centers
for Disease Control and Prevention (CDC) growth chart \(^{79}\), respectively. The Tanita body fat monitor (Tanita Corporation, Illinois, USA) was used to measure fat mass percentage (%FM) to determine adiposity in participants\(^{15}\).

**Quantification of plasma leptin levels using ELISA.** Fasting plasma samples were collected by centrifuging EDTA-treated whole blood at 1,500 g for 15 minutes at room temperature. Plasma samples were aliquoted and stored in cryovials at \(–80\) °C until further use. On the day of the assay, plasma samples were thawed on ice and centrifuged once at 1,500 g for 15 minutes at room temperature. Plasma samples were diluted, and leptin levels were quantified using the commercially available enzyme linked immunosorbent assay (ELISA), Human Leptin Quantikine ELISA Kit (R&D Systems, Minneapolis, USA) as per manufacturer’s guidelines.

**Statistical analysis.** SPSS versions 24.0 and 25.0 were used to perform all statistical analyses\(^{80}\). Categorical variables are presented as counts (%) and continuous variables are reported as means (SD). Outliers were determined using visual inspection and box plots, and the Shapiro-Wilk test was used to determine normality of the data distribution\(^{81}\). Non-normally distributed data were log-transformed for inclusion in the analyses. In the case of missing data, multiple imputations were used.

Correlation analyses were conducted using a Pearson zero-order correlation test and partial correlation test unadjusted and age, sex, and puberty-adjusted values. Multivariable linear regression analysis was used to determine whether leptin is associated with total or central adiposity with the independent variables including age, sex, puberty, and cancer status. Results are reported as standardized \(\beta\) coefficients and associated p-values. We also conducted unstandardized coefficients testing with resulting B values with 95% confidence intervals (CI) and p-values. Since the results for both trends in the same direction, we report only the results of the standardized testing in Table 3. Statistical significance was set at \(\alpha = 0.05\).

Received: 22 July 2019; Accepted: 28 February 2020; Published online: 13 March 2020

**References**

1. McAloon, C. I. et al. The changing face of cardiovascular disease 2000–2012: An analysis of the world health organisation global health estimates data. *International journal of cardiology* **224**, 256–264 (2016).
2. Heron, M. P. Deaths: Leading causes for 2015 (2017).
3. Bhattacharya, P., Wickramasinghe, K., Williams, J., Rayner, M. & Townsend, N. The epidemiology of cardiovascular disease in the UK 2014. *Heart* **101**, 1182–1189 (2015).
4. Townsend, N. et al. Cardiovascular disease in Europe: epidemiological update 2016. *European heart journal* **37**, 3232–3245 (2016).
5. Green, D. M., Hyland, A., Chung, C. S., Zevon, M. A. & Hall, B. C. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. *Journal of Clinical Oncology* **17**, 3207–3215 (1999).
6. Heikens, J. et al. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. *Cancer* **88**, 2116–2121 (2000).
7. Mulrooney, D. A. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *Bmj* **339**, b606 (2009).
8. Armstrong, G. T. et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. *J Clin Oncol* **27**, 2328–2338 (2009).
9. Meacham, L. R. et al. Diabetes mellitus in long-term survivors of childhood cancer: increased risk associated with radiation therapy: a report for the childhood cancer survivor study. *Archives of Internal medicine* **169**, 1381–1388 (2009).
10. Gurney, J. G. et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. *Cancer* **97**, 663–673 (2003).
11. Bowers, D. C. et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study; *Journal of Clinical Oncology* **24**, 5277–5282 (2006).
12. Fall, T. et al. Age- and sex-specific causal effects of adiposity on cardiovascular risk factors. *Diabetes* **64**, 1841–1852 (2015).
13. Rana, J. S., Li, T. Y., Manson, J. E. & Hu, F. B. Adiposity compared with physical inactivity and risk of type 2 diabetes in women. *Diabetes care* **30**, 53–58 (2007).
14. Wang, K. W. et al. Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and meta-analysis. *Clinical Obesity* (2017).
15. Wang, K. W. et al. Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECI). *Scientific reports* **7**, 45078 (2017).
16. Siviero-Miachon, A. A., Spinola-Castro, A. M. & Guerra-Junior, G. Adiposity in childhood cancer survivors: insights into obesity physiopathology. *Arquivos Brasileiros de Endocrinologia & Metabologia* **53**, 190–200 (2009).
17. Steinberger, J. et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. *The Journal of Pediatrics* **160**, 494–499 (2012).
18. Meacham, L. R. et al. Body mass index in long-term adult survivors of childhood cancer: A report of the Childhood Cancer Survivor Study. *Cancer: Interdisciplinary International Journal of the American Cancer Society* **103**, 1730–1739 (2005).
19. Juonala, M. et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. *New England Journal of Medicine* **365**, 1876–1885 (2011).
20. Reilly, J. J. & Kelly, J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. *International journal of obesity* **35**, 891 (2011).
21. Baker, J. L., Olsen, L. W. & Serensen, T. I. A. Childhood body mass index and the risk of coronary heart disease in adulthood. *New England journal of medicine* **337**, 2329–2337 (2007).
22. Whitaker, R. C., Wright, J. A., Pepe, M. S., Seidell, J. K. & Dietz, W. H. Predicting obesity in young adulthood from childhood and parental obesity, *New England Journal of Medicine* **337**, 869–873 (1997).
23. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**, 425 (1994).
24. Schwartz, M. W., Peskind, E., Raskind, M., Boyko, E. J. & Porte, D. Jr Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. *Nature medicine* **2**, 589 (1996).
25. Zimmet, P. et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. *Bmj* **313**, 965–969 (1996).
26. Ostlund, R. E. Jr, Yang, J. W., Klein, S. & Gingerich, R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. *The journal of clinical endocrinology & metabolism* **81**, 3909–3913 (1996).
27. McNeely, M. J. et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. *Diabetes Care* **22**, 65–70 (1999).

28. Schmidt, M. I. et al. Leptin and incident type 2 diabetes: risk or protection? *Diabetologia* **49**, 2086–2096 (2006).

29. Franks, P. W. et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. *Obesity* **13**, 1476–1484 (2005).

30. Wallace, A. M. et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). *Circulation* **104**, 3052–3056 (2001).

31. Galletti, F. et al. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. *The Journal of Clinical Endocrinology & Metabolism* **93**, 3922–3926 (2008).

32. Shalitin, S. et al. Endocrine outcome in long-term survivors of childhood brain tumors. *Hormone research in paediatrics* **76**, 113–122 (2011).

33. Merchant, T. E. et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. *International Journal of Radiation Oncology*Biology*Physics* **45**, 45–50 (2000).

34. Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. *CA: a cancer journal for clinicians* **64**, 83–103 (2014).

35. Chambless, L. E., Parker, S. L., Hassam-Malani, L., McGirt, M. J. & Thompson, R. C. Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. *Journal of neuro-oncology* **106**, 383–389 (2012).

36. Mertens, A. C. et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. *Journal of Clinical Oncology* **19**, 3163–3172 (2001).

37. Prasad, P. K., Signorello, L. B., Friedman, D. L., Boice, J. D. & Pukkala, E. Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland. *Pediatric blood & cancer* **58**, 421–427 (2012).

38. Lustig, R. H. et al. Risk Factors for the Development of Obesity in Children Surviving Brain Tumors. *J Clin Endocrinol Metab* **88**, 611–616 (2003).

39. Pui, C. H. et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children’s Research Hospital, 1992 through 2007. *J Clin Oncol* **30**, 2005–2012 (2012).

40. Samaan, M. C. & Akhtar-Danesh, N. The impact of age and race on longevity in pediatric astrocytic tumors: A population-based study. *Pediatric blood & cancer* (2015).

41. Roth, C., Wilken, B., Hanefeld, F., Schroter, W. & Leonhardt, U. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. *138*, 89 (1998).

42. Shaikh, M. G., Grundy, R. G. & Kirk, J. M. Hyperleptinaemia rather than fasting hyperinsulinaemia is associated with obesity following hypothalamic damage in children. *European journal of endocrinology* **159**, 791–797 (2008).

43. Green, E. D. et al. The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. *Genome Research* **5**, 5–12 (1995).

44. Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. *Cell* **83**, 1263–1271 (1995).

45. Bingham, N. C., Anderson, K. K., Reuter, A. L., Stallings, N. R. & Parker, K. L. Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome. *Endocrinology* **149**, 2138–2148 (2008).

46. Couce, M. E., Burguera, B., Parisi, J. E., Jensen, M. D. & Lloyd, R. V. Localization of leptin receptor in the human brain. *Neuroendocrinology* **66**, 145–150 (1997).

47. Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. *Science* **290**, 669–677 (1995).

48. Lustig, R. H. et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. *The journal of clinical investigation* **96**, 2065–2070 (1995).

49. Vannakouila, M. et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. *The Journal of Clinical Endocrinology & Metabolism* **88**, 1730–1736 (2003).

50. Eriksson, J. et al. Leptin concentrations and their relation to body fat distribution and weight loss: A prospective study in individuals with impaired glucose tolerance. *Hormone and metabolic research* **31**, 616–619 (1999).

51. Thong, F. S. H., Hudson, R., Ross, R., Janssen, I. & Graham, T. E. Plasma leptin in moderately obese men: independent effects of weight loss and aerobic exercise. *American Journal of Physiology-Endocrinology and Metabolism* **279**, E307–E313 (2000).

52. Kimura, Y. et al. Association of adulthood weight gain with circulating adipokine and insulin resistance in the Japanese population. *European journal of clinical nutrition* **69**, 462 (2015).

53. Havel, P. J. et al. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. *The Journal of Clinical Endocrinology & Metabolism* **81**, 4406–4413 (1996).

54. Valle, M. et al. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. *International journal of obesity* **27**, 13 (2003).

55. Wabitsch, M. et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. *The journal of clinical investigation* **100**, 808–813 (1997).

56. Saad, M. F. et al. Sexual dimorphism in plasma leptin concentration. *The Journal of Clinical Endocrinology & Metabolism* **82**, 579–584 (1997).

57. Montague, C. T. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* **387**, 903 (1997).

58. Farooqi, I. S. et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *The journal of clinical investigation* **110**, 1093–1102 (2002).

59. Zhang, Y. & Scarpone, P. J. The role of leptin in leptin resistance and obesity. *Physiology & behavior* **88**, 249–256 (2006).

60. Martin, S. S., Qusim, A., & Reilly, M. P. Leptin resistance: a possible interfac, S. IL inflammation and metabolism in obesity-related cardiovascular disease. *Journal of the American College of Cardiology* **52**, 1201–1210 (2008).

61. Scarpone, P. J., Matheny, M., Tümer, N., Cheng, K. Y. & Zhang, Y. Leptin resistance exacerbates diet-induced obesity and is associated with diminished maximal leptin signalling capacity in rats. *Diabetologia* **48**, 1075–1083 (2005).

62. Lin, S., Thomas, T. C., Storlien, L. H. & Huang, X. F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6j mice. *International journal of obesity* **24**, 639 (2000).

63. Glennemsen, C. et al. Gut-brain cross-talk in metabolic control. *Cell* **168**, 758–774 (2017).

64. Heimfelds, S. B. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. *Jama* **282**, 1568–1575 (1999).

65. Zeliusen, P. M. J. et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. *Diabetes, Obesity and Metabolism* **7**, 755–761 (2005).

66. Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *New England Journal of Medicine* **334**, 292–295 (1996).
70. Trevaskis, J. L. et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. *Endocrinology* **149**, 5679–5687 (2008).
71. Trevaskis, J. L., Parkes, D. G. & Roth, J. D. Insights into amylin–leptin synergy. *Trends in Endocrinology & Metabolism* **21**, 473–479 (2010).
72. Müller, T. D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. *Journal of Peptide Science* **18**, 383–393 (2012).
73. Chen, K. Y. et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. *The Journal of Clinical Endocrinology & Metabolism* **100**, 1639–1645 (2015).
74. Unniappan, S. & Kieffer, T. J. Leptin extends the anorectic effects of chronic PYY (3-36) administration in ad libitum-fed rats. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* **295**, RS1–R38 (2008).
75. Wang, L., Barachina, M. D., Martinez, V., Wei, J.-Y. & Tache, Y. Synergistic interaction between CCK and leptin to regulate food intake. *Regulatory peptides* **92**, 79–85 (2000).
76. Samaan, M. C., Thabane, L., Burrow, S., Dillenburg, R. F. & Scheinemann, K. Canadian Study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE study): a cohort study protocol examining the mechanisms of obesity in survivors of childhood brain tumours. *BMJ open* **3**, e002869 (2013).
77. Samaan, M. C. et al. Recruitment feasibility to a cohort study of endocrine and metabolic health among survivors of childhood brain tumours: a report from the Canadian study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE). *BMJ Open* **4**, e005295 (2014).
78. Nihiser, A. I. et al. Body mass index measurement in schools. *J Sch Health* **77**, 651–671; quiz 722–654 (2007).
79. Kuczmerski, R. J. et al. 2000 CDC Growth Charts for the United States: methods and development. *Vital Health Stat 11*, 1–190 (2002).
80. Released, S. I. PASW Statistics for Windows, Version 24. (2016).
81. Ghasemi, A. & Zahediasl, S. Normality tests for statistical analysis: a guide for non-statisticians. *International journal of endocrinology and metabolism* **10**, 486 (2012).

Acknowledgements
We would like to thank all of the participants and their families for participation in the study.

Author contributions
The guarantor of this study is M.C.S. The research question and study design were developed by M.C.S., W.J.J., B.E., A.F., C.P., D.L.J., S.M.Z., S.R.R., S.B., and L.T. E.D.S. was partly responsible for the recruitment of participants and data collection. A.F., C.P., B.E., S.B., D.L.J., S.R.R. and S.M.Z. supported the recruitment and data collection process. W.J.J. performed the ELISA leptin analysis and assisted in the statistical analysis. Research methods and statistical analyses support were provided by M.C.S. and L.T. E.D.S., W.J.J., B.E. and M.C.S. drafted the manuscript and the final version was reviewed by all authors, who agreed with its contents.

Competing interests
M.C.S. was funded by the Pediatric Oncology Group of Ontario Research Unit and Hamilton Health Sciences and Foundation. E.D.S. received funding from the Canada Graduate Scholarship-Master’s from the Canadian Institutes of Health Research (CIHR) B.E. received funding from Regional Medical Associates (RMA) Hamilton. The funding agencies had no input into proposing the research question, study design, data collection, statistical analysis or the conclusions of the paper.

Additional information
Correspondence and requests for materials should be addressed to M.C.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020